Orally administered anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel anti-inflammatory personalized therapeutic approach

Personalized therapies are designed to optimize the safety-to-efficacy ratio by selecting patients with higher response rates based on specific biomarkers. Inflammation plays a vital role in the pathogenesis of non-alcoholic steatohepatitis (NASH), a common liver disorder. Eotaxin-1 plays a role in...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoury, Tawfik, Rotnemer-Golinkin, Dory, Zolotarev, Lidya, Ilan, Yaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287423/
https://www.ncbi.nlm.nih.gov/pubmed/34275345
http://dx.doi.org/10.1177/20587384211021215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287423/
https://www.ncbi.nlm.nih.gov/pubmed/34275345
http://dx.doi.org/10.1177/20587384211021215

Ejemplares similares